Watson Confirms Vigamox Patent Challenge

Watson Pharmaceuticals, Inc. WPI today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market Moxifloxacin Hydrochloride Ophthalmic Solution USP, 0.5%. Watson's Moxifloxacin Hydrochloride Ophthalmic Solution USP, 0.5% is a generic version of Alcon, Inc.'s Vigamox®, an antibiotic solution that is indicated for the treatment of bacterial conjunctivitis.